Advances in the use of prodrugs for drug delivery to the eye
- 21 July 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 14 (1) , 49-63
Abstract
Introduction: Ocular drug delivery is presented with many challenges, taking into account the distinctive structure of the eye. The prodrug approach has been, and is being, employed to overcome such barriers for some drug molecules, utilizing a chemical modification approach rather than a formulation-based approach. A prodrug strategy involves modification of the active moiety into various derivatives in a fashion that imparts some advantage, such as membrane permeability, site specificity, transporter targeting and improved aqueous solubility, over the parent compound. Areas covered: The following review is a comprehensive summary of various novel methodologies and strategies reported over the past few years in the area of ocular drug delivery. Some of the strategies discussed involve polymer and lipid conjugation with the drug moiety to impart hydrophilicity or lipophilicity, or to target nutrient transporters by conjugation with transporter-specific moieties and retrometabolic drug design. Expert opinion: The application of prodrug strategies provides an option for enhancing drug penetration into the ocular tissues, and overall ocular bioavailability, with minimum disruption of the ocular diffusion barriers. Although success of the prodrug strategy is contingent on various factors, such as the chemical structure of the parent molecule, aqueous solubility and solution stability, capacity of targeted transporters and bioreversion characteristics, this approach has been successfully utilized, commercially and therapeutically, in several cases.Keywords
Funding Information
- U.S. Department of Health and Human Services National Institutes of Health (1R01EY025365-01)
This publication has 141 references indexed in Scilit:
- Targeted lipid based drug conjugates: A novel strategy for drug deliveryInternational Journal of Pharmaceutics, 2012
- In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye diseaseEuropean Journal of Pharmaceutics and Biopharmaceutics, 2012
- A novel retinoblastoma therapy from genomic and epigenetic analysesNature, 2012
- Dry Eye DiseaseArchives of Ophthalmology (1950), 2012
- Serine Side Chain-Linked Peptidomimetic Conjugates of Cyclic HPMPC and HPMPA: Synthesis and Interaction with hPEPT1Molecular Pharmaceutics, 2010
- Elucidation of the Self-Assembly Pathway of Lanreotide Octapeptide into β-Sheet Nanotubes: Role of Two Stable IntermediatesJournal of the American Chemical Society, 2010
- Functional characterization of peptide transporters in MDCKII–MDR1 cell line as a model for oral absorption studiesInternational Journal of Pharmaceutics, 2007
- Beta-blocker eyedrops and nocturnal arterial hypotensionAmerican Journal of Ophthalmology, 1999
- Ocular-Specific Delivery of Timolol by Sequential Bioactivation of its Oxime and Methoxime AnalogsJournal of Ocular Pharmacology and Therapeutics, 1997
- Minimal cardiac electro-physiological activity of alprenoxime, a site-activated ocular β-blocker, in dogsLife Sciences, 1995